Report
Oussema Denguir

GlaxoSmithKline : Moving towards a more innovative GSK ... but not immediately (>2020e)

>Good Q2 2018 numbers. Upgraded full-year guidance. - GSK reported its Q2 2018 earnings midday yesterday. It is a good set of figures, with sales growth of 4% cc (Pharma +1% cc/ Vaccines +16% cc/ CHC +3% cc), 1% better than the consensus. Note an excellent showing from the new vaccine Shingrix against zona which posted sales of £ 167m in the quarter (vs £ 117m expected by the consensus), prompting management to forecast full-year sales of between £ 600m and £ 650m (co...
Underlying
GlaxoSmithKline PLC CEDEAR

Provider
Oddo BHF
Oddo BHF

​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Analysts
Oussema Denguir

Other Reports on these Companies
Other Reports from Oddo BHF
Matthias Desmarais
  • Matthias Desmarais

ResearchPool Subscriptions

Get the most out of your insights

Get in touch